Da lægemidlet imidlertid har en ny virkningsmåde, få bivirkninger og en anderledes sikkerhedsprofil end de eksisterende antidepressiva, konkluderede Udvalget, at Thymanax kan være en god behandling for nogle patienter, når blot deres leverfunktion bliver kontrolleret hyppigt.
However, since the medicine has a new mode of action, few side effects and a different safety profile to existing antidepressants, the Committee concluded that Thymanax could be a valuable treatment for some patients as long as their liver function is tested frequently.